Form 4: Whitehawk Therapeutics CEO Awarded Stock Options and Restricted Stock Units
SEC Form 4 Filing
Whitehawk Therapeutics CEO David James Lennon was granted stock options and restricted stock units on April 1, 2025, according to a Form 4 filing.
Summary
- David James Lennon, CEO of Whitehawk Therapeutics, was granted stock options and restricted stock units (RSUs) on April 1, 2025.
- The stock options grant covers 775,828 shares with an exercise price of $1.70 per share.
- These options vest over four years, starting with 25% vesting on the one-year anniversary of April 1, 2025, and the remainder vesting monthly thereafter.
- The RSU grant also covers 775,828 shares, each representing a contingent right to receive one share of Whitehawk Therapeutics common stock.
- The RSUs vest 100% on the one-year anniversary of April 1, 2025.
- Both the stock options and RSU grants are contingent upon Lennon continuing to be a service provider to Whitehawk Therapeutics.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. The sentiment is neutral to slightly positive.
Positives
- The grants of stock options and RSUs align the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedules encourage long-term commitment from the CEO.
Risks
- The value of the stock options and RSUs is dependent on the future performance of Whitehawk Therapeutics' stock.
- If the CEO leaves the company before the options and RSUs fully vest, he will forfeit the unvested portion.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the equity grants.
Industry Context
Equity compensation is a common practice in the biotechnology industry to attract and retain top talent and align their interests with those of shareholders. The vesting schedules are typical for such grants.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation tools for CEOs in the biotech industry.
- Vesting schedules of four years for options and one year for RSUs are within the typical range observed at comparable companies.
- Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize the CEO to improve company performance.
- Employees may see the grants as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of the stock option and RSU grants, and the Vesting Commencement Date. |
| 04/01/2035 | Expiration date of the stock options. |
| 04/03/2025 | Date of the Form 4 filing. |
Keywords
stock options, restricted stock units, RSU, Whitehawk Therapeutics, CEO, David James Lennon, equity compensation, Form 4, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.